Skip to main content
SpringerLink
Log in

Elagolix in endometriosis-related pain: a profile of its use as approved in the USA

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Elagolix (Orilissa™), an oral non-peptide gonadotropin-releasing hormone receptor antagonist, is approved for the management of moderate to severe pain associated with endometriosis in the USA and Canada. It reduces levels of gonadotropins, thereby suppressing ovarian sex hormones, ovulation, and endometrial proliferation. In phase 3 trials in women with moderate to severe endometriosis-related pain, elagolix 150 mg once daily and 200 mg twice daily improved clinical response rates for dysmenorrhea and non-menstrual pelvic pain to a significantly greater extent than placebo at 3 and 6 months of treatment. Improvements from baseline in several other endometriosis pain-related outcomes were also better with elagolix than with placebo, with the benefits of treatment being maintained with treatment for an additional 6 months in extension studies. Elagolix is generally well tolerated, with most adverse events being of mild to moderate severity. However, elagolix is associated with a dosage-dependent risk of bone loss, which limits its duration of therapy, use in at-risk patients, and concomitant use with certain drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Greene AD, Lang SA, Kendziorski JA, et al. Endometriosis: where are we and where are we going? Reproduction. 2016;152(3):R63–R78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ferrero S, Barra F, Maggiore ULR. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018;78:995–1012.

    Article  CAS  PubMed  Google Scholar 

  3. Giudice LC. Endometriosis. N Engl J Med. 2010;362(25):2389–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015;11(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  5. Ferrero S, Esposito F, Abbamonte LH, et al. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. 2005;83(3):573–9.

    Article  PubMed  Google Scholar 

  6. Nnoaham KE, Hummelshojc L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–73.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Soliman AM, Yang H, Du EX, et al. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod. 2016;31(4):712–22.

    Article  PubMed  Google Scholar 

  8. Lamb YN. Elagolix: first global approval. Drugs. 2018;78(14):1501–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ng J, Chwalisz K, Carter DC, et al. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–91.

    Article  PubMed  Google Scholar 

  10. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–51.

    Article  CAS  PubMed  Google Scholar 

  11. Orilissa™ (elagolix) tablets, for oral use: US prescribing information. North Chicago (IL): AbbVie Inc.; 2018.

  12. Orilissa™ (elagolix) 150 mg and 200 mg tablets: Canadian product monograph. St-Laurent (QC): AbbVie Corporation; 2018.

  13. Archer D, Ng J, Chiu YL, et al. Dose-dependent suppression of ovulation and ovarian activity by elagolix in healthy premenopausal women [abstract]. Reprod Sci. 2017;24(1 Suppl 1):140A.

    Google Scholar 

  14. Acs N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord. 2015;7(2):56–62.

    Google Scholar 

  15. Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363–71.

    Article  CAS  PubMed  Google Scholar 

  16. Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ng J, Salem A, Carter D, et al. Effect of the coadministration of ketoconazole on the  pharmacokinetics and safety of elagolix in healthy premenopausal females [abstract no. PI-090]. Clin Pharmacol Ther. 2016;99(Suppl 1):S55.

    Google Scholar 

  18. Ng J, Salem A, Carter D, et al. Effects of the coadministration of multiple doses of elagolix on the pharmacokinetics and safety of digoxin in healthy women [abstract]. Clin Pharmacol Drug Dev. 2017;6(Suppl 1):54–5.

    Google Scholar 

  19. Polepally AR, Dufek MB, Dharia SP, et al. Drug-drug interaction of midazolam with elagolix, a novel oral GnRH antagonist: analyses of data from two studies [abstract]. In: 2017 Annual Meeting of the American College of Clinical Pharmacology. 2017.

  20. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.

    Article  CAS  PubMed  Google Scholar 

  21. Diamond MP, Simon J, Lessey BA, et al. The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain [abstract no. O-232]. Fertil Steril. 2016;106(3 Suppl):e94–5.

    Article  Google Scholar 

  22. Ng J, Klein CE, Duan WR, et al. Pharmacokinetics of elagolix, a novel oral gonadotropin-releasing hormone (GNRH) antagonist administered to female subjects with hepatic impairment [abstract no. PII-110]. Clin Pharmacol Ther. 2015;97 (Suppl 1):S93.

  23. Winzenborg I, Nader A, Polepally AR, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018;57(10):1295–306.

    Article  CAS  PubMed  Google Scholar 

  24. Carr B, Giudice L, Dmowski WP, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometr Pelvic Pain Disord. 2013;5(3):105–15.

    PubMed  PubMed Central  Google Scholar 

  25. Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–60.

    Article  CAS  PubMed  Google Scholar 

  26. Leyland N, Surrey E, Soliman AM, et al. Baseline burden of endometriosis-associated pain among women in two phase 3 elagolix studies [abstract no. 10Q]. Obstet Gynecol. 2018;131(Suppl 1):186S–7S.

    Article  Google Scholar 

  27. Singh S, Lessey BA, Martinez M, et al. Reductions in endometriosis-associated pain among elagolix-treated women are consistent across a range of baseline characteristics [abstract no. O-198]. Fertil Steril. 2018;110(Suppl 4):e84.

    Article  Google Scholar 

  28. Taylor HS, Diamond M, Surrey E, et al. Decreased rescue analgesic use with elagolix treatment in women with endometriosis-associated pain [abstract no. 35G]. Obstet Gynecol. 2018;131(Suppl 1):84S–5S.

    Article  Google Scholar 

  29. Leyland N, Taylor HS, Archer DF, et al. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain [abstract no. O-193]. Fertil Steril. 2018;110 (4 Suppl):e82-e83.

    Article  Google Scholar 

  30. Diamond M, Soliman AM, Castelli-Haley J, et al. Elagolix reduces fatigue in patients with moderate-to-severe endometriosis pain [abstract no. 34G]. Obstet Gynecol. 2018;131(Suppl 1):84S.

    Google Scholar 

  31. Agarwal SK, Soliman AM, Schwefel B, et al. Impact of elagolix on health-related quality of life among patients with moderate to severe endometriosis-associated pain: analysis of EQ-5D-5L data from a phase III randomized controlled trial [abstract no. PIH25]. Value Health. 2018;21(Suppl 1):S144–S145.

    Article  Google Scholar 

  32. Diamond M, Soliman AM, Snabes MC, et al. Productivity gains associated with treatment with elagolix for endometriosis-associated pain [abstract no. PIH24]. Value Health. 2018;21(Suppl 1):S144.

    Article  Google Scholar 

  33. Archer D, Flores OA, Leyland N, et al. Bone turnover changes in women treated with elagolix or placebo during the Elaris EM-I and EM-II trials who did not continue in the extension studies [abstract no. O-25]. Fertil Steril. 2018;110(4 Suppl):e12.

    Article  Google Scholar 

  34. Ng J, Salem A, Carter D, et al. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females [abstract no. PI-089]. Clin Pharmacol Ther. 2016;99(Suppl 1):S54–S55

    Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by S. Ferrero, Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy, and others. During the peer review process, AbbVie Inc., the marketing-authorization holder of elagolix, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Katherine Ann Lyseng-Williamson

Authors
  1. Katherine Ann Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Ann Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Elagolix in endometriosis-related pain: a profile of its use as approved in the USA. Drugs Ther Perspect 35, 110–118 (2019). https://doi.org/10.1007/s40267-019-00606-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-019-00606-y

Search

Navigation